Predictors of deteriorating cerebral infarct: Role of inflammatory mechanisms. Would its early treatment be useful?

被引:36
作者
Castillo, J [1 ]
Leira, R [1 ]
机构
[1] Univ Santiago de Compostela, Hosp Clin, Neurol Serv, Dept Neurol, E-15706 Santiago, Spain
关键词
progressing stroke; early deterioration; inflammatory mechanisms;
D O I
10.1159/000049124
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The development of neurological deterioration in the hours following the stroke onset occurs in somewhat more than 1 in 3 cerebral infarcts and is associated with an increase in morbidity and mortality. This early deterioration (0-48/72 h) entails the conversion of the ischemic penumbra area in an irreversible lesion, a process that is mediated as much by hemodynamic changes in the local cerebral circulation as by biochemical mechanisms. Late neurological deterioration (3-7 days) is more frequently associated with systemic causes. Knowledge of the various clinical, biochemical and imaging markers associated with neurological deterioration is consequently of fundamental importance. For their repercussion in clinical practice, we classify these predictors of deteriorating cerebral infarct into nonmodifiable, modifiable and possibly modifiable. The reduction in cerebral blood flow in a particular cerebral zone causes very early cerebral damage as a consequence of a significant liberation of neuroexcitatory amino acids, followed by an excessive entry of calcium into the interior of cells; this process causes lipid peroxidation, disintegration of the cellular membranes, nuclear destruction and neuronal death. Moreover, ischemia and posterior reperfusion induce an inflammatory response leading to further cellular destruction. It is therefore conceivable that therapeutic interventions aimed at decreasing proinflammatory cytokines and cell adhesion molecules might result in better outcome in this population. Copyright (C) 2001 S.Karger AG, Basel.
引用
收藏
页码:40 / 48
页数:9
相关论文
共 72 条
[1]   LEUKOCYTE-ENDOTHELIAL INTERACTIONS AND REGULATION OF LEUKOCYTE MIGRATION [J].
ADAMS, DH ;
SHAW, S .
LANCET, 1994, 343 (8901) :831-836
[2]   Antithrombotic treatment of ischemic stroke among patients with occlusion or severe stenosis of the internal carotid artery - A report of the Trial of Org 10172 in Acute Stroke Treatment (TOAST) [J].
Adams, HP ;
Bendixen, BH ;
Leira, E ;
Chang, KC ;
Davis, PH ;
Woolson, RF ;
Clarke, WR ;
Hansen, MD .
NEUROLOGY, 1999, 53 (01) :122-125
[3]   INTRACRANIAL BLOOD-FLOW VELOCITIES IN ACUTE ISCHEMIC STROKE [J].
ALEXANDROV, AV ;
BLADIN, CF ;
NORRIS, JW .
STROKE, 1994, 25 (07) :1378-1383
[4]   Prediction of stroke outcome with echoplanar perfusion- and diffusion-weighted MRI [J].
Barber, PA ;
Darby, DG ;
Desmond, PM ;
Yang, Q ;
Gerraty, RP ;
Jolley, D ;
Donnan, GA ;
Tress, BM ;
Davis, SM .
NEUROLOGY, 1998, 51 (02) :418-426
[5]   INTERLEUKIN-6 AND INTERLEUKIN-1 RECEPTOR ANTAGONIST IN ACUTE STROKE [J].
BEAMER, NB ;
COULL, BM ;
CLARK, WM ;
HAZEL, JS ;
SILBERGER, JR .
ANNALS OF NEUROLOGY, 1995, 37 (06) :800-805
[6]   THE ASSOCIATION OF HYPERGLYCEMIA WITH CEREBRAL EDEMA IN STROKE [J].
BERGER, L ;
HAKIM, AM .
STROKE, 1986, 17 (05) :865-871
[7]  
CACABELOS P, 1998, NEUROLOGIA, V13, P458
[8]   Nitric oxide-related brain damage in acute ischemic stroke [J].
Castillo, J ;
Rama, R ;
Dávalos, A .
STROKE, 2000, 31 (04) :852-857
[9]   Glutamate is a marker for cerebral ischemia in cortical but not deep infarcts [J].
Castillo, J ;
Davalos, A ;
Lema, M ;
Serena, J ;
Noya, M .
CEREBROVASCULAR DISEASES, 1997, 7 (05) :245-250
[10]   Progression of ischaemic stroke and excitotoxic aminoacids [J].
Castillo, J ;
Davalos, A ;
Noya, M .
LANCET, 1997, 349 (9045) :79-83